Showing results (1-10 of 48) with videos related to
Sort By:
Pageof 5
Annals of the New York Academy of Sciences|December 24, 2011
The oxazolidinones: past, present, and futureKaren Joy Shaw, Michael R BarbachynJournal of Fungi (Basel, Switzerland)|September 22, 2022
GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive AspergillosisKaren Joy ShawJournal of Medicinal Chemistry|October 12, 2023
Identification of a 1,2,4-Oxadiazole with Potent and Specific Activity against Clostridioides difficile, the Causative Bacterium of C. difficile Infection, an Urgent Public Health ThreatMichael R BarbachynCurrent Opinion in Pharmacology|October 16, 2003
Transcriptional profiling and drug discoveryKaren Joy Shaw, Brian J MorrowJournal of Bacteriology|November 5, 2003
A novel family of Escherichia coli toxin-antitoxin gene pairsJason M Brown, Karen Joy ShawJournal of Fungi (Basel, Switzerland)|October 27, 2020
Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal InfectionsKaren Joy Shaw, Ashraf S IbrahimAngewandte Chemie (International Ed. in English)|May 15, 2003
Oxazolidinone structure-activity relationships leading to linezolidMichael R Barbachyn, Charles W FordAntimicrobial Agents and Chemotherapy|September 16, 2009
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700)Jeffrey B Locke, Mark Hilgers, Karen Joy ShawAntimicrobial Agents and Chemotherapy|October 7, 2009
Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical originJeffrey B Locke, Mark Hilgers, Karen Joy ShawClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2013
Tedizolid for the management of human infections: in vitro characteristicsJeffrey B Locke, Gary E Zurenko, Karen Joy Shaw, et al.Pageof 5